Figure 2.
The amount of different sphingolipids in the serum type 2 diabetes mellitus patients with mild cognitive impairment (MCI) versus normal cognition (NC) were evaluated using targeted sphingolipidomic analysis and were presented in Figure 2 . Evaluation of the total amount of different sphingolipids in MCI and NC groups revealed no significant differences between ceramides (p = 0.47), CerG2GNAc1 (p=0.46), ceramide phosphates (CerP, p=0.67), phosphorylethanolamine ceramides (CerPE, p=0.69), monohexosylceramides (Hex1Cer, p=0.09), dihexosylceramides (Hex2Cer, p=0.62), trihexosyl ceramides (Hex3Cer, p=0.35), sphingomyelins (SM, p=0.92), sphingosine (SP, p=0.8), sphingosine-1-phosphate (SPH, p=0.9) as well as phytosphingomelins (phSM, p=0.37).